ATOR-1015 and the anti-CTLA-4 antibody reduced tumor growth, prolonged survival and cured tumor-bearing mice (complete responders: 1/10 for vehicle; 2/10 for anti-OX40; 6/10 for anti-CTLA-4; 7/10 for ATOR-1015). This evidence concerns the gene TNFRSF4 and neoplasm.